Shifting paradigms of nontuberculous mycobacteria in cystic fibrosis

Respiratory Research

Terese L Katzenstein²  Niels Høiby¹  Tania Pressler²  Tavs Qvist² 

[1] Department of Clinical Microbiology, University Hospital Rigshospitalet, Copenhagen, Denmark;Department of Infectious Diseases, Cystic Fibrosis Center Copenhagen, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark

关键词: Lung transplantation;    Transmission;    Biofilm;    MOTT;    Environmental mycobacteria;    Massiliense;    Avium;    Abcessus;    Mycobacterium;    MAC;    MABSC;    Cystic fibrosis;    Nontuberculous mycobacteria;    NTM;   

Others  :  790344
DOI  :  10.1186/1465-9921-15-41

 received in 2013-11-01, accepted in 2014-04-04,  发布年份 2014

【 摘 要 】

Important paradigms of pulmonary disease with nontuberculous mycobacteria (NTM) are currently shifting based on an increasing attention within the field of cystic fibrosis (CF). These shifts are likely to benefit the management of all patients with pulmonary NTM, regardless of underlying pathology. Currently several key areas are being revised: The first outbreak of human NTM transmission has been proven and new evidence of biofilm growth in vivo has been demonstrated. A better understanding of the clinical impact of NTM infection has led to increased diagnostic vigilance and new recommendations for lung transplantation are under way. While recent changes have reinvigorated the interest in NTM disease, the challenge remains, whether such advances can be successfully translated into improved management and care.

【 授权许可】

   
2014 Qvist et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Torrens JK, Dawkins P, Conway SP, Moya E: Non-tuberculous mycobacteria in cystic fibrosis. Thorax 1998, 53(0040–6376 (Print)):182-185.
• [2]Griffith DE, Aksamit T, Brown-Elliott B a, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, Iseman M, Olivier K, Ruoss S, von Reyn CF, Wallace RJ, Winthrop K, Wallace RJ Jr: An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007, 175:367-416.
• [3]El HG, Viola GM, Hachem R, Han XY, Raad II: Rapidly growing mycobacterial bloodstream infections. Lancet Infect Dis 2013, 13(1474–4457 (Electronic)):166-174.
• [4]Kulka K, Hatfull G, Ojha AK: Growth of Mycobacterium tuberculosis Biofilms. J Vis Exp 2012, 60(60):e3820. doi:10.3791/3820
• [5]Qvist T, Eickhardt-Sørensen S, Pressler T, Katzenstein TL, Andersen CB, Iversen M, Bjarnsholt T, Hoiby N: First evidence of Mycobacterium abscessus biofilm in the lungs of chronically infected CF patients. J Cyst Fibros 2013, 12(Suppl. 1):S2-S2.
• [6]Jönsson BE, Bylund J, Johansson BR, Telemo E, Wold AE: Cord-forming mycobacteria induce DNA meshwork formation by human peripheral blood mononuclear cells. Pathog Dis 2013, 67:54-66.
• [7]Howard ST, Rhoades E, Recht J, Pang X, Alsup A, Kolter R, Lyons CR, Byrd TF: Spontaneous reversion of Mycobacterium abscessus from a smooth to a rough morphotype is associated with reduced expression of glycopeptidolipid and reacquisition of an invasive phenotype. Microbiology 2006, 152(Pt 6):1581-1590.
• [8]Giovannini D, Cappelli G, Jiang L, Castilletti C, Colone A, Serafino A, Wannenes F, Giaco L, Quintiliani G, Fraziano M, Nepravishta R, Colizzi V, Mariani F: A new Mycobacterium tuberculosis smooth colony reduces growth inside human macrophages and represses PDIM Operon gene expression. Does an heterogeneous population exist in intracellular mycobacteria? Microb Pathog 2012, 53(1096–1208 (Electronic)):135-146.
• [9]Catherinot E, Clarissou J, Etienne G, Ripoll F, Emile J-FF, Daffé M, Perronne C, Soudais C, Gaillard J-LL, Rottman M, Daffe M: Hypervirulence of a rough variant of the Mycobacterium abscessus type strain. Infect Immun 2007, 75:1055-1058.
• [10]Pang JM, Layre E, Sweet L, Sherrid A, Moody DB, Ojha A, Sherman DR: The polyketide Pks1 contributes to biofilm formation in Mycobacterium tuberculosis. J Bacteriol 2012, 194:715-721.
• [11]Kreutzfeldt KM, McAdam PR, Claxton P, Holmes A, Seagar AL, Laurenson IF, Fitzgerald JR: Molecular longitudinal tracking of Mycobacterium abscessus spp. during chronic infection of the human lung. PLoS One 2013, 8:e63237.
• [12]Bjarnsholt T, Jensen PO, Fiandaca MJ, Pedersen J, Hansen CR, Andersen CB, Pressler T, Givskov M, Hoiby N: Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009, 44(1099–0496 (Electronic)):547-558.
• [13]Hoiby N, Ciofu O, Johansen HK, Song ZJ, Moser C, Jensen PO, Molin S, Givskov M, Tolker-Nielsen T, Bjarnsholt T: The clinical impact of bacterial biofilms. Int J Oral Sci 2011, 3(1674–2818 (Print)):55-65.
• [14]Zelazny AM, Root JM, Shea YR, Colombo RE, Shamputa IC, Stock F, Conlan S, McNulty S, Brown-Elliott BA, Wallace RJ Jr, Olivier KN, Holland SM, Sampaio EP: Cohort study of molecular identification and typing of Mycobacterium abscessus, Mycobacterium massiliense, and Mycobacterium bolletii. J Clin Microbiol 2009, 47(1098-660X (Electronic)):1985-1995.
• [15]Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA: Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013, 381(1474-547X (Electronic)):1551-1560.
• [16]Pressler T, Karpati F, Granström M, Knudsen PK, Lindblad A, Hjelte L, Olesen HV, Meyer P, Høiby N, Granstrom M, Hoiby N: Diagnostic significance of measurements of specific IgG antibodies to Pseudomonas aeruginosa by three different serological methods. J Cyst Fibros 2009, 8(1569–1993 (Print)):37-42.
• [17]Pressler T, Bohmova C, Conway S, Dumcius S, Hjelte L, Hoiby N, Kollberg H, Tummler B, Vavrova V: Chronic Pseudomonas aeruginosa infection definition: EuroCareCF Working Group report. J Cyst Fibros 2011, 10 Suppl(10 Suppl):S75-S78. 1873–5010 (Electronic)
• [18]Ferroni A, Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, Offredo C, Rottman M, Guillemot D, Bernède C, Vincent V, Berche P, Gaillard J-LL, Le BM, Bernede C: Measurement of immunoglobulin G against Mycobacterial antigen A60 in patients with cystic fibrosis and lung infection due to Mycobacterium abscessus. Clin Infect Dis 2005, 40(1537–6591 (Electronic)):58-66. 1537–6591 (Electronic)
• [19]Oliver A, Maiz L, Canton R, Escobar H, Baquero F, Gomez-Mampaso E: Nontuberculous mycobacteria in patients with cystic fibrosis. Clin Infect Dis 2001, 32(1058–4838 (Print)):1298-1303.
• [20]Qvist T, Pressler T, Katzenstein TL, Hoiby N: Elevated levels of antibodies against Mycobacterium abscessus in cystic fibrosis patients is associated with active lung disease. Pediatr Pulmonol 2012, 3(47 Suppl):335. 1099–0496 (Electronic)
• [21]Smith MJ, Efthimiou J, Hodson ME, Batten JC: Mycobacterial isolations in young adults with cystic fibrosis. Thorax 1984, 39:369-375.
• [22]Hjelte L, Petrini B, Källenius G, Strandvik B, Kallenius G: Prospective study of mycobacterial infections in patients with cystic fibrosis. Thorax 1990, 45(0040–6376 (Print)):397-400.
• [23]Kilby JM, Gilligan PH, Yankaskas JR, Highsmith WE Jr, Edwards LJ, Knowles MR: Nontuberculous mycobacteria in adult patients with cystic fibrosis. Chest 1992, 102(0012–3692 (Print)):70-75.
• [24]Aitken ML: Nontuberculous mycobacterial disease in adult cystic fibrosis patients. CHEST J 1993, 103:1096.
• [25]Hjelt K, Hojlyng N, Howitz P, Illum N, Munk E, Valerius NH, Fursted K, Hansen KN, Heltberg I, Koch C: The role of Mycobacteria Other Than Tuberculosis (MOTT) in patients with cystic fibrosis. Scand J Infect Dis 1994, 26(0036–5548 (Print)):569-576.
• [26]Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, Offredo C, Guillemot D, Halley S, Akoua-Koffi C, Vincent V, Sivadon-Tardy V, Ferroni A, Berche P, Scheinmann P, Lenoir G, Gaillard J-LL, Le BM: Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003, 9:1587-1591.
• [27]Fauroux B, Delaisi B, Clément A, Saizou C, Moissenet D, Truffot-Pernot C, Tournier G, Vu Thien H: Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997, 16:354-358.
• [28]Mussaffi H, Rivlin J, Shalit I, Ephros M, Blau H: Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005, 25(0903–1936 (Print)):324-328.
• [29]Esther CR Jr, Esserman DA, Gilligan P, Kerr A, Noone PG, Esther CR: Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010, 9:117-123.
• [30]Pierre-Audigier C, Ferroni A, Sermet-Gaudelus I, Le BM, Offredo C, Vu-Thien H, Fauroux B, Mariani P, Munck A, Bingen E, Guillemot D, Quesne G, Vincent V, Berche P, Gaillard JL: Age-related prevalence and distribution of nontuberculous mycobacterial species among patients with cystic fibrosis. J Clin Microbiol 2005, 43(0095–1137 (Print)):3467-3470.
• [31]Radhakrishnan DK, Yau Y, Corey M, Richardson S, Chedore P, Jamieson F, Dell SD: Non-tuberculous mycobacteria in children with cystic fibrosis: isolation, prevalence, and predictors. Pediatr Pulmonol 2009, 44:1100-1106.
• [32]Levy I, Grisaru-Soen G, Lerner-Geva L, Kerem E, Blau H, Bentur L, Aviram M, Rivlin J, Picard E, Lavy A, Yahav Y, Rahav G: Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008, 14:378-384.
• [33]Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee JH, Zhang Y, Brown-Elliot BA, Handler A, Wilson RW, Schechter MS, Edwards LJ, Chakraborti S, Knowles MR: Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003, 167(1073-449X (Print)):828-834.
• [34]Roux AL, Catherinot E, Ripoll F, Soismier N, Macheras E, Ravilly S, Bellis G, Vibet MA, Le RE, Lemonnier L, Gutierrez C, Vincent V, Fauroux B, Rottman M, Guillemot D, Gaillard JL: Multicenter study of prevalence of nontuberculous mycobacteria in patients with cystic fibrosis in france. J Clin Microbiol 2009, 47(1098-660X (Electronic)):4124-4128.
• [35]Valenza G, Tappe D, Turnwald D, Frosch M, König C, Hebestreit H, Abele-Horn M: Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J Cyst Fibros 2008, 7:123-127.
• [36]Chalermskulrat W, Sood N, Neuringer IP, Hecker TM, Chang L, Rivera MP, Paradowski LJ, Aris RM: Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation. Thorax 2006, 61(0040–6376 (Print)):507-513.
• [37]Binder AM, Adjemian J, Olivier KN, Prevots DR: Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med 2013, 188:807-812.
• [38]Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR: Opportunistic pathogens enriched in showerhead biofilms. Proc Natl Acad Sci USA 2009, 106(1091–6490 (Electronic)):16393-16399.
• [39]Saiman L, Siegel J: Infection control in cystic fibrosis. Clin Microbiol Rev 2004, 17(0893–8512 (Print)):57-71.
• [40]Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, Degroote MA, Ordway DJ, Rubinsztein DC, Floto RA: Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest 2011, 121(1558–8238 (Electronic)):3554-3563.
• [41]Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD: Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014, 11:36-44.
• [42]Russell CD, Claxton P, Doig C, Seagar A-L, Rayner A, Laurenson IF: Non-tuberculous mycobacteria: a retrospective review of Scottish isolates from 2000 to 2010. Thorax 2013. Epub ahead of print
• [43]Catherinot E, Roux AL, Vibet MA, Bellis G, Ravilly S, Lemonnier L, Le RE, Bernede-Bauduin C, Le BM, Herrmann JL, Guillemot D, Gaillard JL: Mycobacterium avium and Mycobacterium abscessus complex target distinct cystic fibrosis patient subpopulations. J Cyst Fibros 2013, 12(1873–5010 (Electronic)):74-80.
• [44]Esther CR Jr, Henry MM, Molina PL, Leigh MW: Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005, 40(8755–6863 (Print)):39-44.
• [45]Olivier KN, Weber DJ, Lee J-HH, Handler A, Tudor G, Molina PL, Tomashefski J, Knowles MR: Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J RespirCrit Care Med 2003, 167(1073-449X (Print)):835-840.
• [46]Cullen AR, Cannon CL, Mark EJ, Colin AA: Mycobacterium abscessus infection in cystic fibrosis. Colonization or infection? Am J RespirCrit Care Med 2000, 161(1073-449X (Print)):641-645.
• [47]Aitken ML, Limaye A, Pottinger P, Whimbey E, Goss CH, Tonelli MR, Cangelosi GA, Dirac MA, Olivier KN, Brown-Elliott BA, McNulty S, Wallace RJ Jr: Respiratory outbreak of Mycobacterium abscessus subspecies massiliense in a lung transplant and cystic fibrosis center. Am J RespirCrit Care Med 2012, 185(1535–4970 (Electronic)):231-232.
• [48]Jonsson BE, Gilljam M, Lindblad A, Ridell M, Wold AE, Welinder-Olsson C: Molecular epidemiology of Mycobacterium abscessus, with focus on cystic fibrosis. J Clin Microbiol 2007, 45(0095–1137 (Print)):1497-1504.
• [49]Qvist T, Pressler T, Thomsen VO, Skov M, Iversen M, Katzenstein TL: Nontuberculous Mycobacterial Disease Is Not a Contraindication to Lung Transplantation in Patients with Cystic Fibrosis: A Retrospective Analysis in a Danish Patient Population. Transplant Proc 2012, 45(1873–2623 (Electronic)):342-345.
• [50]Gilljam M, Schersten H, Silverborn M, Jonsson B, Ericsson HA: Lung transplantation in patients with cystic fibrosis and Mycobacterium abscessus infection. J Cyst Fibros 2010, 9(1873–5010 (Electronic)):272-276.
• [51]Chernenko SM, Humar A, Hutcheon M, Chow CW, Chaparro C, Keshavjee S, Singer LG: Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006, 25(1557–3117 (Electronic)):1447-1455.
• [52]Griffith DE: Therapy of nontuberculous mycobacterial disease. Curr Opin Infect Dis 2007, 20(0951–7375 (Print)):198-203.
• [53]Waters V, Ratjen F: Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis. Cochrane Database Syst Rev 2012, 12(1469-493X (Electronic)):CD010004.
• [54]Miwa S, Shirai M, Toyoshima M, Shirai T, Yasuda K, Yokomura K, Yamada T, Masuda M, Inui N, Chida K, Suda T, Hayakawa H: Efficacy of clarithromycin and ethambutol for Mycobacterium avium complex pulmonary disease. A preliminary study. Ann Am Thorac Soc 2014, 11:23-9.
• [55]Olivier KN, Shaw PA, Glaser TS, Bhattacharyya D, Fleshner M, Brewer CC, Zalewski CK, Folio LR, Siegelman JR, Shallom S, Park IK, Sampaio EP, Zelazny AM, Holland SM, Prevots DR: Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc 2014, 11:30-5.